Literature DB >> 7460468

Impairment of antipyrine metabolism by low-dose oral contraceptive steroids.

D R Abernethy, D J Greenblatt.   

Abstract

The effect of low-dose oral contraceptive steroids (OCS) on the kinetics of intravenous antipyrine was determined. Eight women (age, 23.1 +/- 1.1 yr (mean +/- SE); weight, 57.8 +/- 2.2 kg) using low-dose (less than or equal to 50 micrograms) estrogen oral contraceptive steroids (OCS) on a long-term basis were age- and weight-matched with eight controls (age, 23.4 +/- 0.8 yr; weight, 58.4 +/- 2.1 kg) not using OCS. All were nonsmokers taking no other drugs. OCS subjects had a longer antipyrine elimination half-life (t1/2 beta) than the controls (17.3 +/- 1.6 and 10.5 +/- 0.8 hr; p less than 0.005). Volume of distribution was similar for both groups (0.59 +/- 0.02 l/kg [OCS] and 0.58 +/- 0.02 l/kg). Total metabolic clearance of antipyrine was slowed in OCS subjects (0.41 +/- 0.03 and 0.66 +/- 0.05 ml/min/kg; p less than 0.001). Since volume of distribution and body weight are of the same order in both groups, prolongation of antipyrine t1/2 beta is the result of decreased total metabolic clearance. Thus, even low-dose estrogen containing OCS may impair clearance of other drugs.

Entities:  

Keywords:  Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Family Planning; Mestranol; Metabolic Effects; Norethindrone; Norethynodrel; Oral Contraceptives; Oral Contraceptives, Combined; Oral Contraceptives, Low-dose; Physiology; Research Methodology; Retrospective Studies; Steroid Metabolic Effects; Studies

Mesh:

Substances:

Year:  1981        PMID: 7460468     DOI: 10.1038/clpt.1981.17

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Pharmacokinetics of brotizolam in the elderly.

Authors:  R Jochemsen; K L Nandi; D Corless; J G Wesselman; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1983       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of oral contraceptive steroids.

Authors:  M L Orme; D J Back; A M Breckenridge
Journal:  Clin Pharmacokinet       Date:  1983 Mar-Apr       Impact factor: 6.447

3.  Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids.

Authors:  E C Rietveld; M M Broekman; J J Houben; T K Eskes; J M van Rossum
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives.

Authors:  D R Abernethy; E L Todd
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam.

Authors:  R Jochemsen; M van der Graaff; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

6.  Effect of chronic oral contraceptive steroids on theophylline disposition.

Authors:  K M Tornatore; R Kanarkowski; T L McCarthy; M J Gardner; A M Yurchak; W J Jusko
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 7.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

8.  Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol.

Authors:  H R Ochs; D J Greenblatt; B Verburg-Ochs; J S Harmatz; H Grehl
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  Antipyrine elimination in saliva after low-dose combined or progestogen-only oral contraceptive steroids.

Authors:  D M Chambers; G C Jefferson; M Chambers; N B Loudon
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

10.  Accuracy and clinical utility of simplified tests of antipyrine metabolism.

Authors:  G C Farrell; L Zaluzny
Journal:  Br J Clin Pharmacol       Date:  1984-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.